Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ON 123300 (Narazaciclib) Dose Escalation in Advanced Cancer
NCT04739293Phase 1Recruiting
- Sponsor
- Traws Pharma, Inc.
- Start
- May 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of narazaciclib in solid tumor and non-Hodgkin lymphoma (NHL), sponsored by Traws Pharma, Inc. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days, Incidence of adverse events and 1 more. Started May 2021; status: recruiting.
02
Drugs
narazaciclib
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04739293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04739293.